Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics (Nasdaq: NTLA) reported Q2 2026 results and updates. It said Phase 3 HAELO data for lonvo-z in hereditary angioedema met primary and key secondary endpoints, with an 87% attack reduction vs placebo. Intellia expects FDA BLA acceptance in H2 2026 and a U.S. launch in H1 2027. Cash was $628.4M, funding operations into 2028.
How this was made
The 30-second read
Why it matters
The most tradable elements are the quantified Phase 3 HAELO efficacy results and management’s explicit expectations for FDA BLA acceptance in 2H26 and a potential U.S. launch in 1H27, alongside a stated cash runway into 2028.
Market read
This is a company-specific catalyst package combining Phase 3 efficacy, regulatory timing expectations, and balance-sheet runway, which can reprice approval probability and launch expectations.
What to watch
The article notes HLA-linked transaminase elevations for nex-z and ongoing FDA engagement, which could become a future overhang even as lonvo-z advances.
Background
Intellia is advancing two in vivo CRISPR programs: lonvo-z for hereditary angioedema (HAE) and nex-z for transthyretin (ATTR) amyloidosis, with Regeneron as a collaboration partner for nex-z.
Ticker impact
Intellia reports positive Phase 3 HAELO lonvo-z data, expects FDA BLA acceptance in 2H26, and targets U.S. launch in 1H27.
Near-term upside bias on sentiment and probability of approval, with follow-through dependent on FDA acceptance and any remaining safety/regulatory questions.
The article discloses primary endpoint success with quantified attack-rate reductions, plus explicit FDA acceptance and launch timing expectations, which are direct drivers of valuation for a pre-commercial biotech.
Market effects
Reinforces investor appetite for in vivo CRISPR gene-editing platforms with near-term regulatory milestones.
Limited direct regional spillover; primarily U.S. biotech sentiment and FDA-readiness expectations.
EAACI and NEJM publication support global credibility of the HAELO dataset, potentially influencing international payer and investigator confidence.
Counterpoint
Despite strong efficacy, FDA acceptance and eventual approval remain uncertain; any regulatory pushback on safety or durability could offset the positive read-through.
Key entities
- companyIntellia Therapeutics, Inc.
Reports Q2 2026 results and updates on lonvo-z Phase 3 HAELO and nex-z Phase 3 ATTR programs.
- product_candidatelonvo-z (Lonvoguran Ziclumeran)
In vivo CRISPR gene-editing candidate for hereditary angioedema; Phase 3 HAELO met primary and key secondary endpoints.
- product_candidatenex-z (Nexiguran Ziclumeran)
In vivo CRISPR candidate for ATTR amyloidosis; enrollment reinitiated and genomic analysis highlights HLA-linked transaminase elevations.
- collaboration_partnerRegeneron Pharmaceuticals, Inc.
Collaborator on nex-z development and commercialization; collaboration revenue decline attributed to reduced Regeneron revenue.
- regulatorU.S. Food and Drug Administration (FDA)
Expected to accept the lonvo-z BLA submission in the second half of 2026, per company guidance.
